CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 92 enrolled
Drug / intervention
Fimasartan 60 mg group +2 moredrug
Likely dose
Fimasartan 60 mg groupfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00922441
NCT00922441Phase 2Completed
CompareCT.gov

A Randomized, Double-blind, Valsartan-Referenced, Parallel Grouped, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan(BR-A-657•K) During 24hours by Dose in Patients With Mild to Moderate Essential Hypertension

Boryung Pharmaceutical Co., Ltd·interventional·Posted Jun 17, 2009·Updated Mar 15, 2018

In Brief

A Phase 2 clinical trial evaluating Fimasartan 60 mg group, Fimasartan 120 mg group, and 1 other intervention for Essential Hypertension. Completed, enrolled 92 participants.

Detailed Summary

The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan (BR-A-657•K) during 24 hours by dose in patients with mild to moderate essential hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
Countries--
CollaboratorsSeoul National University Hospital, Kyungpook National University Hospital, Catholic Medical Center, Inje University, Chonnam National University Hospital

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 17, 2009
Enrollment StartDec 1, 2008
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.0 years ago

Interventions

Fimasartan 60 mg groupdrug

Fimasartan 60 mg

Fimasartan 120 mg groupdrug

Fimasartan 120 mg

Reference (Valsartan 80 mg) groupdrug

Reference (Valsartan 80 mg)